Mostrar o rexistro simple do ítem
26,26,26,27,27,27-Hexadeuterated-1,25-Dihydroxyvitamin D3 (1,25D-d6) As Adjuvant of Chemotherapy in Breast Cancer Cell Lines
dc.contributor.author | Seoane, Samuel | |
dc.contributor.author | Bermúdez, María José | |
dc.contributor.author | Sendón Lago, Juan José | |
dc.contributor.author | Martínez Ordóñez, Anxo | |
dc.contributor.author | Abdul-Hadi, Soraya | |
dc.contributor.author | Maestro, Miguel | |
dc.contributor.author | Mouriño, Antonio | |
dc.contributor.author | Pérez-Fernández, Román | |
dc.date | 2013 | |
dc.date.accessioned | 2017-09-26T08:09:08Z | |
dc.date.available | 2017-09-26T08:09:08Z | |
dc.identifier.citation | Cancers 2014, Vol. 6, Pages 67-78 | es_ES |
dc.identifier.issn | 2072-6694 | |
dc.identifier.uri | http://hdl.handle.net/2183/19529 | |
dc.description.abstract | It has been demonstrated that 1,25-dihydroxyvitamin D3 (1,25D) and some of its analogues have antitumor activity. 1,25D labeled with deuterium (26,26,26,27,27,27-hexadeuterated 1a,25-dihydroxyvitamin D3, or 1,25D-d6) is commonly used as internal standard for 1,25D liquid chromatography-mass spectrometry (LC-MS) quantification. In the present study using human breast cancer cell lines, the biological activity of 1,25D-d6 administered alone and in combination with two commonly used antineoplastic agents, 5-fluorouracil and etoposide, was evaluated. Using an MTT assay, flow cytometry, and western blots, our data demonstrated that 1,25D-d6 has effects similar to the natural hormone on cell proliferation, cell cycle, and apoptosis. Furthermore, the combination of 1,25D-d6 and etoposide enhances the antitumoral effects of both compounds. Interestingly, the antitumoral effect is higher in the more aggressive MDA-MB-231 breast cancer cell line. Our data indicate that 1,25D-d6 administered alone or in combination with chemotherapy could be a good experimental method for accurately quantifying active 1,25D levels in cultures or in biological fluids, on both in vitro breast cancer cell lines and in vivo animal experimental models. | es_ES |
dc.description.sponsorship | Ministerio de Economía y Competividad; SAF2012-38240 | es_ES |
dc.description.sponsorship | Ministerio de Educación e Innovación. MEI; SAF2010-15291 | es_ES |
dc.description.sponsorship | Xunta de Galicia; CN2012/074 | es_ES |
dc.description.sponsorship | Xunta de Galicia; INCITE08PXIB209130PR | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Multidisciplinary Digital Publishing Institute | es_ES |
dc.relation.uri | http://dx.doi.org/10.3390/cancers6010067 | es_ES |
dc.rights | Reconocimiento 3.0 | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/ | |
dc.subject | 1a,25-dihydroxyvitamin d<sub>3</sub> | es_ES |
dc.subject | 26,26,26,27,27,27-hexadeuterated 1a,25-dihydroxyvitamin d<sub>3</sub> | es_ES |
dc.subject | Vitamin d | es_ES |
dc.subject | Deuterated vitamin d | es_ES |
dc.subject | Chemotheraphy | es_ES |
dc.subject | Breast cancer | es_ES |
dc.title | 26,26,26,27,27,27-Hexadeuterated-1,25-Dihydroxyvitamin D3 (1,25D-d6) As Adjuvant of Chemotherapy in Breast Cancer Cell Lines | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.access | info:eu-repo/semantics/openAccess | es_ES |
UDC.journalTitle | Cancers | es_ES |
UDC.volume | 6 | es_ES |
UDC.issue | 1 | es_ES |
UDC.startPage | 67 | es_ES |
UDC.endPage | 78 | es_ES |